
    
      The investigation is a pivotal, prospective, multicenter, open-label single arm study
      evaluating treatment with hepatic arterial injection of SIR-Spheres.

      Up to 100 subjects will be treated (up to 150 consented) at 10-15 clinical sites in the
      United States.

      The population for this study is patients diagnosed with HCC BCLC stage A, B1, and B2 with
      maximal single lesion size of â‰¤ 8cm and who are not considered suitable for treatment by
      resection or eligible for ablation at time of study entry.
    
  